JYLAMVO is a folate analog metabolic inhibitor indicated for the: Treatment of adults with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen (1.1)...
Jylamvo: Package Insert / Prescribing Information - Drugs.com
2024年11月10日 · Jylamvo package insert / prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology.
Jylamvo - European Medicines Agency (EMA)
Jylamvo is an anti-inflammatory and cancer medicine used to treat the following conditions: active rheumatoid arthritis (a disease causing inflammation in joints) in adults; severe juvenile idiopathic arthritis (inflammation of joints in children) in patients from 3 years of age when NSAIDs (non-steroidal anti-inflammatory drugs) have not ...
Jylamvo is for use in the following indications: In rheumatological and dermatological diseases • Active rheumatoid arthritis in adult patients. • Polyarthritic forms of active, severe juvenile idiopathic arthritis (JIA) in adolescents and children aged 3 years and over when the response tonon -steroidal anti-inflammatory drugs
Jylamvo Oral: Uses, Side Effects, Interactions, Pictures ... - WebMD
Jylamvo 2 Mg/Ml Oral Solution Folate Antagonists - Uses, Side Effects, and More. Generic Name (S): methotrexate. Uses. Methotrexate is used to treat certain types of cancer (such as acute...
Shorla Oncology Announces U.S. FDA Expanded Approval of Jylamvo …
2024年10月29日 · Jylamvo is an easy-to-administer, orange flavored solution that eliminates the need for crushing or splitting pills, or compounding into a liquid formulation. Jylamvo offers advantages because it remains stable at room temperature (68°F to 77°F) for 90 days and does not require cold chain storage pre-dispense. About Shorla Oncology
Jylamvo Advanced Patient Information - Drugs.com
2024年3月28日 · Detailed drug Information for Jylamvo. Includes common brand names, drug descriptions, warnings, side effects and dosing information.
What is Jylamvo and what is it used for? Jylamvo is an anti-inflammatory and cancer medicine used to treat the following conditions: • active rheumatoid arthritis (a disease causing inflammation in joints) in adults;
Jylamvo® (methotrexate) – New drug approval. On November 29, 2022, the FDA approved Therakind’s Jylamvo (methotrexate) oral solution, for the treatment of: — Adults with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen — Adults with mycosis fungoides (cutaneous T-cell lymphoma) as a single ...
Shorla Oncology & EVERSANA Announce U.S. Commercial Launch …
2023年12月19日 · JYLAMVO is the first and only oral methotrexate solution approved in the United States for use in adults, it has shown to have a sweet, palatable taste*, is stable at room temperature (68°F to 77°F) for 90 days and does not require refrigeration.